MA43532A - Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques - Google Patents

Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques

Info

Publication number
MA43532A
MA43532A MA043532A MA43532A MA43532A MA 43532 A MA43532 A MA 43532A MA 043532 A MA043532 A MA 043532A MA 43532 A MA43532 A MA 43532A MA 43532 A MA43532 A MA 43532A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
disorders related
epileptic seizures
Prior art date
Application number
MA043532A
Other languages
English (en)
Inventor
David Chernoff
Timothy J Fultz
Sangita Ghosh
Jack Nguyen
Gregory T Went
Original Assignee
Adamas Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharmaceuticals Inc filed Critical Adamas Pharmaceuticals Inc
Publication of MA43532A publication Critical patent/MA43532A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA043532A 2015-12-30 2016-12-30 Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques MA43532A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562273187P 2015-12-30 2015-12-30

Publications (1)

Publication Number Publication Date
MA43532A true MA43532A (fr) 2018-11-07

Family

ID=57838557

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043532A MA43532A (fr) 2015-12-30 2016-12-30 Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques

Country Status (11)

Country Link
US (3) US10973783B2 (fr)
EP (1) EP3397253A1 (fr)
JP (2) JP6902033B2 (fr)
CN (1) CN109069480A (fr)
AU (1) AU2016381366A1 (fr)
BR (1) BR112018012870A2 (fr)
CA (1) CA3008170A1 (fr)
IL (1) IL259861A (fr)
MA (1) MA43532A (fr)
MX (1) MX2018008021A (fr)
WO (1) WO2017117569A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
CN109255370B (zh) * 2018-08-20 2021-07-27 安徽大学 一种基于pauc算法的农田智能喷药方法
TWI879741B (zh) * 2018-10-03 2025-04-11 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
US12042474B2 (en) 2019-06-06 2024-07-23 Shanghai Aucta Pharmaceuticals Co., Ltd. Lacosamide pharmaceutical composition and dosage form thereof
WO2020244615A1 (fr) * 2019-06-06 2020-12-10 上海奥科达生物医药科技有限公司 Composition pharmaceutique de lacosamide et sa préparation pharmaceutique
CN111407738A (zh) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 一种布立西坦控释制剂及其制备方法
CN118267385A (zh) * 2020-07-09 2024-07-02 上海云晟研新生物科技有限公司 一种布瓦西坦药物组合物、其制备方法及应用
TW202300138A (zh) * 2021-03-17 2023-01-01 大陸商上海博志研新藥物技術有限公司 拉考沙胺藥物組合物、其製備方法及應用
CN113244197B (zh) * 2021-05-24 2023-02-28 天方药业有限公司 一种卡马西平缓释胶囊剂及其制备方法
CN115343386B (zh) * 2022-07-25 2024-09-17 南京海纳医药科技股份有限公司 一种hplc-ms/ms联用检测人血浆中吡仑帕奈的方法
CN115326960B (zh) * 2022-08-11 2024-03-15 复旦大学附属华山医院 一种同时检测人血浆中8种抗癫痫药物及1种活性代谢物浓度的分析方法
EP4559457A1 (fr) * 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. Composition de comprimé à libération modifiée de brivaracétam
EP4559456A1 (fr) * 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. Comprimé à libération modifiée de brivaracétam
US12478587B1 (en) 2025-02-06 2025-11-25 Shanghai Aucta Pharmaceuticals Co., Ltd. Formulation for lacosamide

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
US6048899A (en) 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU1534699A (en) 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
US6107492A (en) 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
MXPA01006108A (es) 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6939556B2 (en) 2002-06-26 2005-09-06 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (fr) 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
US20100256179A1 (en) 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
BRPI0510593A (pt) 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
EP1604655A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
JP2006124385A (ja) 2004-09-30 2006-05-18 Takeda Chem Ind Ltd 放出制御製剤
WO2006036007A2 (fr) 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited Preparation a liberation modifiee
EP1642889A1 (fr) 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
WO2006058236A2 (fr) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition et methode pour traiter des affections neurologiques
US20060165745A1 (en) 2005-01-21 2006-07-27 Yiwen Chew Sustained release tablets for treatment of aqueous environment and methods for making the same
EA014249B1 (ru) 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
US20070071819A1 (en) 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
EP1731149A1 (fr) 2005-06-08 2006-12-13 Ucb S.A. Utilisation de Brivaracetam pour le traitement de maladies caracterisées par l'épilepsie myoclonique progressive
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (fr) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
WO2007120485A2 (fr) 2006-03-30 2007-10-25 Cinergen, Llc Procédés de traitement de la douleur avec des alkylxanthines et des antiépileptiques et compositions à utiliser à cet effet
ES2531118T5 (es) 2006-06-15 2022-06-14 Ucb Pharma Gmbh Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
EP1873527A1 (fr) 2006-06-30 2008-01-02 Schwarz Pharma Ag Procédé d'identification des modulateurs CRMP
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2008086492A1 (fr) 2007-01-11 2008-07-17 Xenoport, Inc. Formes galéniques orales à libération prolongée d'un promédicament de r-baclofène et procédés de traitement
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
PT2273975E (pt) 2008-03-03 2014-07-17 Ucb Pharma Sa Processos de preparação e utilizações terapêuticas de soluções farmacêuticas
US20090298947A1 (en) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
CA2722093C (fr) 2008-05-30 2015-04-28 Ucb Pharma, S.A. Compositions pharmaceutiques comprenant du brivaracetam
CA2731008A1 (fr) 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Formulation a liberation modifiee et procedes d'utilisation
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
DK2346500T3 (en) 2008-10-16 2017-07-17 Univ Johns Hopkins Methods and compositions for improving cognitive function
PT2358361T (pt) 2008-11-18 2016-11-18 Ucb Biopharma Sprl Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
CN104208714A (zh) 2008-11-18 2014-12-17 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的延长释放制剂
DE102008059155A1 (de) 2008-11-27 2010-06-02 Ratiopharm Gmbh Trockenverarbeitung und neue Formen von Lacosamid
GB2467312B (en) * 2009-01-28 2013-06-26 Mark Labudek Design Ltd Titanium alloy, a method of producing the alloy and an article made of the alloy
DK2391349T3 (da) 2009-01-29 2014-11-03 Ucb Pharma Sa Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
CA2747396C (fr) 2009-01-29 2015-12-08 Serge Cuypers Compositions pharmaceutiques comprenant des derives de 2-oxo-1-pyrrolidine
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
CN102596897A (zh) 2009-08-06 2012-07-18 麦迪凯姆股份公司 一种n-(苯基甲基)丙酰胺衍生物的多种固体形态及制备方法
ES2753141T3 (es) 2009-11-03 2020-04-07 Lupin Ltd Formulación de liberación modificada de lacosamida
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
WO2011101863A2 (fr) 2010-02-19 2011-08-25 Cadila Healthcare Limited Compositions pharmaceutiques à libération prolongée de lacosamide
WO2011135430A1 (fr) * 2010-04-29 2011-11-03 Lupin Limited Compositions pharmaceutiques à libération contrôlée de brivaracétam
EP2645997B1 (fr) 2010-12-02 2022-08-10 UCB Pharma GmbH Formulation de lacosamide en prise quotidienne unique
EP2468261A1 (fr) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation de lacosamide
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
EP2753331A1 (fr) 2011-09-07 2014-07-16 Novartis AG Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible
KR101732731B1 (ko) 2013-04-02 2017-05-08 주식회사 바이오파마티스 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물
PL2801352T3 (pl) 2013-05-08 2017-12-29 Sanovel Ilac Sanayi Ve Ticaret A.S. Ulegające rozpadowi w jamie ustnej formulacje lakozamidu
EP2801351B1 (fr) 2013-05-08 2018-08-01 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations pharmaceutiques de lacosamide
WO2014180895A1 (fr) 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations pharmaceutiques de lacosamide
WO2015079010A2 (fr) 2013-11-29 2015-06-04 Ucb Pharma Gmbh Composition pharmaceutique comprenant du lacosamide et du lévétiracétam
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物

Also Published As

Publication number Publication date
IL259861A (en) 2018-07-31
CA3008170A1 (fr) 2017-07-06
WO2017117569A1 (fr) 2017-07-06
US20170189342A1 (en) 2017-07-06
JP2019500353A (ja) 2019-01-10
AU2016381366A1 (en) 2018-06-28
EP3397253A1 (fr) 2018-11-07
BR112018012870A2 (pt) 2018-12-04
US20220062204A1 (en) 2022-03-03
US20180161282A1 (en) 2018-06-14
JP6902033B2 (ja) 2021-07-14
US10973783B2 (en) 2021-04-13
JP2021095418A (ja) 2021-06-24
CN109069480A (zh) 2018-12-21
US10987324B2 (en) 2021-04-27
MX2018008021A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3349760A4 (fr) Compositions et méthodes destinées à traiter les troubles neurologiques
EP3344274A4 (fr) Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3433266A4 (fr) Méthodes de traitement de troubles mitochondriaux
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3307754A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles de la peau
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
EP3359258A4 (fr) Compositions et méthodes de traitement de troubles fibreux de la peau
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
MA47212A (fr) Méthodes de traitement de troubles neurologiques
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3347002A4 (fr) Méthodes de traitement de troubles neurodégénératifs dans une population spécifique de patients
EP3621434A4 (fr) Méthodes de traitement de troubles neuropsychiatriques
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
EP2903643A4 (fr) Traitement d'affections psychiatriques
EP2906594A4 (fr) Méthodes et compositions pour le traitement de la sclérose en plaques et de troubles associés
EP3313417A4 (fr) Méthodes de traitement de troubles auto-immuns et allo-immuns
EP3334710A4 (fr) Compositions et méthodes de traitement et de prévention de troubles neurodégénératifs
EP3634370A4 (fr) Traitement des troubles cutanés
MA42985A (fr) Traitement de troubles liés à l'acide biliaire